ORIGINAL ARTICLE
Androgen receptor in male breast cancer
Submission date: 2015-07-10
Acceptance date: 2015-08-06
Publication date: 2016-02-05
Pol J Pathol 2015;66(4):347-352
KEYWORDS
TOPICS
ABSTRACT
We present the androgen receptor (AR) status in 32 breast cancers diagnosed in male patients. Androgen receptor expression was found in 62.5% tumors and it was more frequent (85% of cases) in estrogen-positive tumours. The analyses of its impact on treatment results showed that AR immmunopositivity is a prognostic factor for overall survival, and AR immunonegativity is also correlated with worse prognosis (distant metastases developed more frequently and earlier).
REFERENCES (37)
1.
Johansen Taber KA, Morisy LR, Osbahr AJ 3rd, D, et al. Male breast cancer: risk, diagnosis, and management (Review). Oncol Rep 2010; 24: 1115-1120.
2.
White J, Kearins O, Dodwell D, et al. Male breast carcinoma: increased awareness needed. Breast Cancer Res 2011; 13: 219.
3.
Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat 2009; 115: 429-430.
4.
Anderson WF, Jatoi I, Tse J, et al. Male breast cancer: A population-based comparison with female breast cancer. J Clin Oncol 2010; 28: 232-239.
5.
Gnerlich JL, Deshpande AD, Jeffe DB, et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol 2011; 18: 1837-1844.
6.
Baojiang L, Tingting L, Gang L, et al. Male breast cancer: A retrospective study comparing survival with female breast cancer. Oncology Lett 2012; 4: 642-646.
7.
Gómez-Raposo C, Zambrana Tévar F, Sereno Moyano M, et al. Male breast cancer. Cancer Treat Rev 2010; 36: 451-457.
8.
Zurrida S, Nole F, Bonnanni B, et al. Male breast cancer. Future Oncol 2010; 6: 985-991.
9.
Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology diagnosis, treatment, and survivorship. Ann Oncol 2013; 24: 1434-1443.
10.
Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol 2010; 17: 17-21.
11.
Onami S, Ozaki M, Mortimer JE, et al. Male breast cancer: An update in diagnosis, treatment and molecular profiling. Maturitas 2010; 65: 308-314.
12.
Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002; 137: 678-687.
13.
Jaiyesimi IA, Buzdar AU, Sahin AA, et al. Carcinoma of the male breast. Ann Intern Med 1992; 117: 771-777.
14.
Vaysse C, Sroussi J, Mallon P, et al. Prediction of axillary lymph node status in male breast carcinoma. Ann Oncol 2013; 24: 370-376.
15.
Liu T, Tong Z, He L, et al. Clinopathological characteristics and survival analysis of 87 male breast cancer cases. Breast Care 2011; 6: 446-451.
16.
Sas-Korczynska B, Niemiec J, Harazin-Lechowska A, et al. The biological markers and results of treatment in male breast cancer patients. The Cracow experience. Neoplasma 2014; 61: 333-341.
17.
Samaan NA, Buzdar AU, Aldinger KA, et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer 1981; 47: 554-560.
18.
Schippinger W, Regitnig P, Dandachi N, et al. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 2006; 449: 24-30.
19.
Hu R, Dawood S, Holmes MD, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 2011; 17: 1867-1874.
20.
Peters AA, Buchanan G, Ricciarddelli C, et al. Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer Res 2009; 69: 6131-6140.
21.
Panet-Raymond V, Gottlieb B, Beitel LK, et al. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 2000; 167: 139-150.
22.
Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106(1): djt319. doi: 10.1093/jnci/djt319.
23.
Sutton LM, Cao D, Sarode V, et al. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast cancer. Am J Patol 2012; 138: 511-516.
24.
Castellano I, Allia E, Accortanzo V, et al. Androgen receptor expression is a significant prognostic factor in oestrogen receptor positive breast cancers. Breast Cancer Res Treat 2010; 124: 607-617.
25.
Niemiec J, Sas-Korczynska B, Harazin-Lechowska A, et al. Lymphatic and blood vessels in male breast cancer. Anticancer Res 2015; 35: 1041-1048.
26.
Sas-Korczynska B, Martynow D, Korzeniowski S. Breast cancer in males treated between 1960 and 2010 at the Cancer Centre in Krakow. Nowotwory 2013; 63: 103-110.
27.
Adamczyk A, Niemiec J, Janecka A, et al. Prognostic value of PIK3CA mutation status, PTEN, androgen receptor expression for metastases free survival in HER2 positive breast cancer patients treated with trastuzumab in adjuvant setting. Pol J Pahol 2015; 64: 133-141.
28.
Nieto CM, Rider LC, Cramer SD. Influence of stromal-epithelial interactions on androgen action. Endocrinol Rel Cancer 2014; 21: T147-T160.
29.
Park S, Koo JS, Kim MS, et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancer. Ann Oncol 2011; 22: 1755-1762.
30.
Collins LC, Cole KS, Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses; Health Study. Mod Pathol 2011; 24: 924-931.
31.
Cochrane DR, Bernales S, Jacobsen BM, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 2014; 16: R7.
32.
Tang D, Xu S, Zhang Q, et al. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol 2012; 29: 526-533.
33.
Wenhui Z, Shuo L, Dabei T, et al. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment. Eur J Endocrinol 2014; 171: 527-533.
34.
Maeda T, Nakanishi Y, Hirotani Y, et al. Immunohistochemical co-expression status of cytokeratin 5’6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Med Mol Morphol 2015; doi: 10.1007/s00795-015-0109-0.
35.
He J, Peng R, Yuan Z, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 2012; 29: 406-410.
36.
Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
37.
McGhan LJ, McCullough AE, Protheroe CA, et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol 2014; 21: 361-367.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
